Barclays PLC cut shares of United Therapeutics Corp. (NASDAQ:UTHR) from an equal weight rating to an underweight rating in a research report released on Tuesday. The brokerage currently has $100.00 price objective on the biotechnology company’s stock, down from their prior price objective of $115.00.

Several other equities research analysts have also recently weighed in on UTHR. Cowen and Company set a $144.00 price target on shares of United Therapeutics Corp. and gave the company a buy rating in a research report on Thursday, October 27th. Ladenburg Thalmann raised shares of United Therapeutics Corp. from a neutral rating to a buy rating and raised their target price for the stock from $128.00 to $138.00 in a research report on Friday, October 28th. Wedbush reaffirmed an outperform rating and issued a $229.00 target price on shares of United Therapeutics Corp. in a research report on Friday, November 4th. Zacks Investment Research raised shares of United Therapeutics Corp. from a hold rating to a buy rating and set a $137.00 target price for the company in a research report on Wednesday, September 28th. Finally, Argus reaffirmed a hold rating on shares of United Therapeutics Corp. in a research report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $133.42.

Analyst Recommendations for United Therapeutics Corp. (NASDAQ:UTHR)

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 126.57 on Tuesday. The firm has a 50-day moving average of $122.42 and a 200-day moving average of $118.39. The company has a market capitalization of $5.37 billion, a P/E ratio of 8.57 and a beta of 1.39. United Therapeutics Corp. has a 12 month low of $97.52 and a 12 month high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.38 by $0.98. The business earned $408.20 million during the quarter, compared to analysts’ expectations of $400.58 million. United Therapeutics Corp. had a net margin of 44.40% and a return on equity of 41.78%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.55 EPS. On average, equities analysts predict that United Therapeutics Corp. will post $16.29 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/united-therapeutics-corp-uthr-lowered-to-underweight-at-barclays-plc.html.

In other news, Director Christopher Patusky sold 5,000 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $122.73, for a total value of $613,650.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at $613,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,233 shares of United Therapeutics Corp. stock in a transaction that occurred on Friday, November 25th. The stock was sold at an average price of $132.81, for a total transaction of $163,754.73. Following the completion of the sale, the chief executive officer now owns 1,373 shares of the company’s stock, valued at $182,348.13. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Oxford Asset Management raised its stake in shares of United Therapeutics Corp. by 62.3% in the second quarter. Oxford Asset Management now owns 154,276 shares of the biotechnology company’s stock worth $16,341,000 after buying an additional 59,246 shares in the last quarter. RDL Financial Inc. raised its stake in shares of United Therapeutics Corp. by 2.1% in the second quarter. RDL Financial Inc. now owns 5,440 shares of the biotechnology company’s stock worth $576,000 after buying an additional 112 shares in the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of United Therapeutics Corp. during the second quarter worth approximately $12,033,000. Chatham Capital Group Inc. raised its stake in shares of United Therapeutics Corp. by 1.2% in the second quarter. Chatham Capital Group Inc. now owns 8,610 shares of the biotechnology company’s stock worth $912,000 after buying an additional 100 shares in the last quarter. Finally, Creative Planning raised its stake in shares of United Therapeutics Corp. by 330.4% in the second quarter. Creative Planning now owns 2,410 shares of the biotechnology company’s stock worth $255,000 after buying an additional 1,850 shares in the last quarter.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.